HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Active antimetastatic immunotherapy in Lewis lung carcinoma with self EGFR extracellular domain protein in VSSP adjuvant.

Abstract
The epidermal growth factor receptor (EGFR) plays a central role in regulating neoplastic processes. The EGFR overexpression in many human epithelial tumors has been correlated with disease progression and bad prognosis. Passive EGFR-directed immunotherapy, but not active specific approaches, has already been introduced in medical oncology practice. Then we wonder if mice immunization with the extracellular domain of murine EGFR (mEGFR-ECD) in adjuvants can circumvent tolerance to self EGFR, by inducing an immune response with consequent antitumor effect. The present study demonstrated that despite mEGFR expression in thymus, strong DTH response was induced by inoculation of mice with the mEGFR-ECD. This self-immunization, using both CFA and very small sized proteoliposomes from Neisseria meningitidis (VSSP), promoted highly specific IgG titers, predominantly IgG2a and IgG2b. Sera from mice immunized with mEGFR-ECD/VSSP not only recognized EGFR+ tumor cell lines by FACS, but also inhibited their in vitro growth, even in the absence of complement. Noteworthy, vaccination of mice with mEGFR-ECD/VSSP stimulated a potent antimetastatic effect in the EGFR+ Lewis lung carcinoma model, while reproduction-associated side effects were absent. Curiously, mice immunized with the human EGFR-ECD (Her1-ECD) in VSSP though induced highly specific IgG antibodies with strong in vitro cytotoxic effect over EGFR+ human cell lines, showed low cross-reactivity with the mEGFR-ECD. These results further encouraged the development of the Her1-ECD/VSSP vaccine project for patients with EGFR+ tumors.
AuthorsBelinda Sánchez Ramírez, Eduardo Suárez Pestana, Greta Garrido Hidalgo, Tays Hernández García, Rolando Pérez Rodríguez, Axel Ullrich, Luis Enrique Férnandez
JournalInternational journal of cancer (Int J Cancer) Vol. 119 Issue 9 Pg. 2190-9 (Nov 01 2006) ISSN: 0020-7136 [Print] United States
PMID16841332 (Publication Type: Journal Article)
Chemical References
  • Adjuvants, Immunologic
  • Recombinant Fusion Proteins
  • ErbB Receptors
Topics
  • Adjuvants, Immunologic (therapeutic use)
  • Animals
  • Cell Line
  • ErbB Receptors (genetics, immunology)
  • Genetic Vectors
  • Humans
  • Immunotherapy
  • Lung Neoplasms (immunology, prevention & control)
  • Mice
  • Neoplasm Metastasis (prevention & control)
  • Recombinant Fusion Proteins (immunology)
  • Reverse Transcriptase Polymerase Chain Reaction
  • Transfection

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: